AP-2α decreases TMZ resistance of recurrent GBM by downregulating MGMT expression and improving DNA damage
AP-2α activation by gene overexpression or RA treatment reveals the suppressive effects on glioma relapse, providing a novel therapeutic strategy against malignant refractory gliomas.
Authors
- Mi Ouyang (ORCID: https://orcid.org/0000-0002-9448-1938)
- Zhe Zhong (ORCID: https://orcid.org/0009-0004-1125-4441)
- Gui‐Xiang Huang (ORCID: https://orcid.org/0000-0003-1223-0164)
- Shengwen Long
- Limin Li (ORCID: https://orcid.org/0000-0002-6470-757X)
- Zhiwei Li (ORCID: https://orcid.org/0000-0002-9375-7138)
- Shuanglin Xiang
- Xiaofeng Ding
- Yiru Zhang
- Kai Xiao (ORCID: https://orcid.org/0000-0002-3070-2789)
- Hao Zhou (ORCID: https://orcid.org/0009-0009-8675-8253)
Institutions
- Central South University (CN)
- Hunan Normal University (CN)
- Changsha Normal University (CN)
- Hunan Cancer Hospital (CN)
- Second Xiangya Hospital of Central South University (CN)
Publication Details
- Journal
- Life Sciences
- Published
- 2024-10-04
- DOI
- https://doi.org/10.1016/j.lfs.2024.123111
- Citations
- 1
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.44
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province